Contrarian takes, anyone? Perhaps one of the cheapest pharma stocks out there, certainly the cheapest large cap pharma stock. Whereas other large pharma stocks market cap is around 3x revenue, Aurobindo is ‘only’ about 1x.
Negatives are too many to count, so the question is not whether it’s a good company. The question is whether all the negatives are priced in or not? If they are, this can be a short term bounceback trade or a value trade.
If not, when does this reach ‘cigar butt’ category? Thoughts welcome.
Disc: A very small position initiated, will average down to a certain extent.
| Subscribe To Our Free Newsletter |
